Your browser doesn't support javascript.
loading
Anodyne by Design; Measuring the Prevalence of Esoteric Designer Opioids in Pain Management Patients.
Goggin, Melissa M; Gozum, Stephanie D; Miller, Anna; Janis, Gregory C.
Afiliação
  • Goggin MM; Department of Research & Development, MedTox Laboratories, Laboratory Corporation of America Holdings, St. Paul, MN, USA.
  • Gozum SD; Department of Research & Development, MedTox Laboratories, Laboratory Corporation of America Holdings, St. Paul, MN, USA.
  • Miller A; Department of Research & Development, MedTox Laboratories, Laboratory Corporation of America Holdings, St. Paul, MN, USA.
  • Janis GC; Department of Research & Development, MedTox Laboratories, Laboratory Corporation of America Holdings, St. Paul, MN, USA.
J Anal Toxicol ; 42(6): 384-391, 2018 Jul 01.
Article em En | MEDLINE | ID: mdl-29471504
ABSTRACT
The recent increase in illicit opioids sold on the black market, cut into heroin and masqueraded as prescription pills prompts a significant public health concern. Most designer opioids possess unknown potencies and unknown pharmacokinetics and their unregulated, variable dosages lead to rashes of overdoses. Additionally, many of the designer opioids, especially the fentanyl analogs are significantly more potent than heroin. High-profile cases involving overdoses of U-47700 and carfentanil have been reported in the media; however, the true prevalence of these and other designer opioids is unknown. Independent LC-MS-MS screen and confirmation methods have been developed and validated to identify and quantify fentanyl, and 18 designer opioids and their metabolites; methods were then exercised on urine specimens from contract pain management clients. Assuming patients in a pain management program may have a higher probability to seek out self-medication, samples from pain management patients were investigated for designer opioids. Similarly, pain management patients identified as using heroin may be more likely to experiment with or be accidentally exposed to designer opioids, specimens screening positive for the heroin metabolite 6-acetylmorphine were specifically chosen for designer opioid screening. Within this small group of pain management and heroin-positive samples, nine designer opioids were detected at a total prevalence of 25%. When screening random pain management samples not positive for heroin, a considerably lower percentage of samples (<1%) were identified as positive for designer opioids. Furanyl fentanyl, fluorobutyryl fentanyl and acetylfentanyl were the most prevalent designer opioids detected in both test groups.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dor / Drogas Desenhadas / Detecção do Abuso de Substâncias / Manejo da Dor / Dependência de Heroína / Analgésicos Opioides Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dor / Drogas Desenhadas / Detecção do Abuso de Substâncias / Manejo da Dor / Dependência de Heroína / Analgésicos Opioides Idioma: En Ano de publicação: 2018 Tipo de documento: Article